LAG3 and cancer: Based on the relative absence of autoimmunity in LAG-3 KO mice, blocking LAG-3 clinically could potentially result in diminished toxicity as compared to blocking other immune checkpoints like CTLA-4, and might render LAG-3 blockade a reasonable partner in combination immunotherapy studies in cancer and in chronic infectious disease.